uniQure (NASDAQ:QURE) Director Jeremy Springhorn Sells 1,993 Shares

uniQure N.V. (NASDAQ:QURE) Director Jeremy Springhorn sold 1,993 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director owned 43,251 shares in the company, valued at approximately $1,170,372.06. This trade represents a 4.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Trading Up 2.8%

Shares of QURE stock opened at $27.57 on Friday. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $22.52 and its two-hundred day moving average is $21.80. The company has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. Equities analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Barclays reduced their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Monday, March 23rd. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Finally, Stifel Nicolaus set a $28.00 price objective on uniQure in a research report on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Torren Management LLC bought a new position in uniQure in the fourth quarter worth $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc bought a new position in uniQure in the fourth quarter worth $48,000. Smartleaf Asset Management LLC bought a new position in uniQure in the fourth quarter worth $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in uniQure in the third quarter worth $50,000. 78.83% of the stock is owned by institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.